

ÖSSUR Q1 RESULTS 2015

Highlights Q1 2015

- Sales amounted to USD 114 million compared to USD 121 million in Q1 2014, corresponding to local currency growth of 5% and 4% organic growth.
- Bracing and supports sales growth was 3% and 3% organic, both measured in local currency.
- Prosthetics sales growth was 9% and 6% organic, both measured in local currency.
- Gross profit amounted to USD 71 million and 63% of sales, compared to USD 76 million and 63% of sales in Q1 2014.
- EBITDA increased by 3% and amounted to USD 21 million or 18% of sales, compared to USD 20 million or 17% of sales in Q1 2014. EBITDA grew by 12% in local currency.
- Net profit decreased by 21% and amounted to USD 9 million or 8% of sales, compared to USD 11 million or 9% of sales in Q1 2014.
- USD strengthening has had a significant impact on reported sales and profits, negatively impacting sales by USD 13 million and EBITDA by USD 2 million.
- Cash generation in the first quarter of the year is seasonally weak and cash generated by operations amounted to USD 7 million or 6% of sales, compared to USD 12 million or 10% of sales in Q1 2014.
- Dividends of USD 7.5 million (DKK 0.12 per share), corresponding to approximately 14% of the Company's net profit in 2014, were paid at the end of March 2015.
- Registration of the share capital reduction of the Company of 7,456,755 shares with a nominal value of ISK 1 each was completed on 15 April 2015.

Financial Guidance for 2015

The financial guidance for the full year of 2015 is reiterated as follows:

- Total sales growth LCY in the range of 4-6%.
- Organic sales growth LCY in the range of 3-5%.
- EBITDA margin in the range of 20-21% of sales.
- Capital expenditures in the range of 2.5-3.5% of sales.
- Effective tax rate around 26%.

Jón Sigurðsson, President & CEO, comments:

"The results of this quarter are in line with our expectations. We delivered strong operational results with good profitability, despite adverse currency fluctuations and the first quarter being seasonally weak for us. Prosthetics sales growth was excellent across all of our major markets and product lines. Sales growth in bracing and supports was in line with expectations. Our continued focus on selling high-end innovative products is contributing nicely to improved product mix and increased profitability."

Conference Call

Össur will host a conference call on Thursday 30th April 2015 at **10:00 CET/ 8:00 GMT/ 4:00 EDT**.

To participate in the call please dial: Europe: + 45 3544 5580, +44 (0) 203 364 5374 or +46 (0) 8 505 564 74,
The United States: + 1 855 753 2230, Iceland: +354 800 7417

Financial Highlights

USD m		Q1 2015	Q1 2014	2014	2013	2012	2011
Income Statement							
Net sales		114	121	509	436	399	398
Gross profit		71	76	323	270	248	246
Operating expenses (excl. other income)		55	60	237	210	191	189
EBIT		16	16	86	60	57	59
Net profit		9	11	59	41	38	35
EBITDA		21	20	104	75	70	73
Sales growth							
Sales growth USD	%	(6)	25	17	9	0	11
Growth breakdown:							
Organic growth in LCY	%	4	6	5	2	3	5
Currency effect	%	(11)	1	(1)	1	(3)	3
Acquired/divested business	%	1	18	13	6	1	4
Balance Sheet							
Total assets		646	706	678	706	591	580
Equity		425	450	442	448	408	365
Net interest-bearing debt (NIBD)		97	116	93	108	82	111
Cash Flow							
Cash generated by operations		7	12	98	73	71	68
Free cash flow		(2)	6	68	49	43	32
Key ratios							
Gross profit margin	%	63	63	63	62	62	62
EBIT margin	%	14	13	17	14	14	15
EBITDA margin	%	18	17	20	17	18	18
Equity ratio	%	66	64	65	63	69	63
Net debt to EBITDA *		0.9	1.4	0.9	1.4	1.2	1.5
Effective tax rate	%	26	26	24	26	26	26
Return on equity *	%	13	11	13	10	10	10
CAPEX / Net sales	%	4.3	2.2	3.3	3.9	3.6	4.1
Market							
Market value of equity		1,366	997	1,311	880	606	676
Number of shares	Millions	446	454	454	454	454	454
Price/earnings ratio, (P/E) *		23.9	21.8	22.1	21.7	15.8	20.0
Diluted EPS	US cent	2.0	2.5	13.1	9.1	8.4	7.7
Diluted cash EPS	US cent	3.0	3.5	17.2	12.5	11.3	10.6

*Financial ratios for Q1 2015 and Q1 2014 are based on operations for the preceding 12 months.

Management's Report

Q1 2015 HIGHLIGHTS

Sales Performance

Sales amounted to USD 114 million compared to USD 121 million in Q1 2014, corresponding to local currency growth of 5% and 4% organic growth.

Sales by Segments and Regions in Q1 2015

USD m	Q1 2015	% of sales	Sales growth USD	Sales growth LCY	Organic sales growth LCY
EMEA	57	50%	-13%	7%	7%
Americas	49	43%	1%	1%	1%
APAC	8	7%	18%	25%	3%
Total	114	100%	-6%	5%	4%

USD m	Q1 2015	% of sales	Sales growth USD	Sales growth LCY	Organic sales growth LCY
Bracing and supports	66	58%	-9%	3%	3%
Prosthetics	48	42%	-2%	9%	6%
Other	0	0%	42%	60%	62%
Total	114	100%	-6%	5%	4%

Bracing and supports

Bracing and supports sales grew by 3% and 3% organic compared to Q1 2014, both measured in local currency. Sales growth was entirely driven by good performance in EMEA, as sales were flat in the Americas and weak in APAC. In EMEA, all major markets contributed to the growth. Soft sales performance in Americas was affected by product rationalization efforts and continued increased focus on selling high end products, which affected sales of other products. Sales growth in APAC was weak this quarter. Sales performance in APAC has historically been volatile between quarters due to relatively high sales to a few large distributors.

Prosthetics

Prosthetics sales grew by 9% and 6% organic compared to Q1 2014, both measured in local currency. Sales performance continued to be good in all major markets in EMEA, Americas and APAC. Össur recently implemented a partnership services program in selected markets that has contributed to enhancing the Company's relationship with its customers and has impacted sales positively.

Sales of bionic products in the quarter accounted for 16% of prosthetic component sales, excluding clinics, compared to 14% in Q1 2014.

Gross Profit

Gross profit amounted to USD 71 million and 63% of sales, compared to USD 76 million and 63% of sales in Q1 2014. The marginal improvement in gross profit margin was driven by favorable product mix changes.

EBITDA

EBITDA increased by 3% and amounted to USD 21 million or 18% of sales, compared to USD 20 million or 17% of sales in Q1 2014. EBITDA grew by 12% in local currency.

The increase in EBITDA was largely a result of favorable product mix changes and efficiency in operations. Currency movements had a marginal positive effect on the EBITDA margin.

The strengthening of the USD against other major operating currencies in Q1 2015 impacted the quarterly operating results negatively compared to Q1 2014; sales by USD 13 million, gross profit by USD 5 million and EBITDA by USD 2 million.

Financial Items, Tax and Net Profit

Net financial expenses amounted to USD 3.8 million compared to USD 0.5 million in Q1 2014. Net exchange rate difference was negative by USD 3.0 million compared to positive USD 0.3 million in Q1 2014. The negative net exchange rate difference was a result of exchange rate impact on bank balances and operating assets and liabilities denominated in currencies that depreciated against the USD.

Income tax amounted to USD 3.2 million, corresponding to a 26% effective tax rate, compared to USD 4 million and 26% effective tax rate in Q1 2014.

Net profit decreased by 21% and amounted to USD 9 million or 8% of sales, compared to USD 11 million or 9% of sales in Q1 2014.

Diluted earnings per share amounted to 2.0 US cents, compared to 2.5 US cents in Q1 2014, corresponding to a decrease of 21%.

Cash Flow

Cash generated by operations amounted to USD 7 million or 6% of sales, compared to USD 12 million or 10% of sales in Q1 2014. Cash generation in the first quarter of the year is seasonally weak and was further impacted by the strengthening of the USD. In addition, investment in working capital was seasonally high and is expected to reverse in the next quarters.

Capital expenditures during the quarter amounted to USD 4.8 million or 4.3% of sales, compared to USD 2.7 million or 2.2% of sales in Q1 2014. Capital expenditures were unusually high in the quarter due to timing of investments. Capital expenditures are expected to be within the range of 2.5-3.5% of sales for the full year.

Capital Structure and Dividends

In accordance with the resolution approved at the Annual General Meeting on 12 March 2015, the share capital of the Company was reduced by ISK 7,456,755 by cancelling the Company's own shares of ISK 1 nominal value each. The registration of the capital reduction was completed on 15 April 2015. The Company currently holds 4,650,000 own shares that may be used to settle share options vesting in 2015.

As approved by the Annual General Meeting, the Company paid a cash dividend of DKK 0.12 per share for 2014 at the end of March 2015, an increase of 20% from 2013 and equivalent to 14% of net profit in 2014.

General Update

Products

In Q1 2015, 6 new products and product upgrades were introduced to the market: 4 bracing and supports products and 2 prosthetic products. Product highlights during the quarter include:

Iceross Seal-In® X, a new liner that provides advanced Seal-In technology for a wider range of users. Iceross Seal-In® X is easier to invert and don, even for less active users who may have hand dexterity issues.

Unity® for Vari-Flex® XC generates elevated vacuum in the prosthetic socket through gait for Vari-Flex® XC.

Shared Service Center

Össur has decided to set up a shared service center for finance back office functions in Poland to further enhance the scalability of finance functions and to support future growth of the company. The shared service center will be operational in Q2 2015. One off costs related to establishing the shared service center is expected to be around USD 1 million in 2015 and USD 1.5 million in 2016. The expected annual savings are estimated to be around USD 1-1.5 million, with full effect from 2017.

FX matters

The financials in the quarter are affected by the strengthening of the USD against major operating currencies. Due to the strengthening of the USD, the absolute numbers in the financials are affected negatively compared to last year. Split of sales and expenses by main currencies can be found in note 4 in the accompanying Consolidated Financial Statements. As can be seen in the note, the EBITDA margin is fairly well hedged for currency movements and one of the key variables for this hedge to hold is that the EUR and the ISK move in tandem to the USD.

Financial Calendar and Upcoming Events and Conferences

Capital Markets Day

Össur invites financial analysts, institutional investors, lenders and financial media to a Capital Markets Day in Copenhagen on 20 May 2015. The Capital Markets Day is hosted by Jón Sigurðsson, President & CEO, along with key members of the management team. Further details on the Capital Markets Day, including the agenda and location, are available at www.ossur.com/investors.

Financial Calendar

Q2 2015 Results	23 July 2015
Q3 2015 Results	22 October 2015
Q4/FY 2015 Results	2 February 2016
2016 Annual General Meeting (IS)	10 March 2016

Upcoming Events and Conferences

DB Healthcare Conference (US)	7 May 2015
Össur's Capital Markets Day (DK)	20 May 2015
Goldman Sachs Healthcare Conference (UK)	9-10 September 2015
Morgan Stanley Healthcare Conference (US)	16-18 September 2015

Further information:

Jón Sigurðsson, President & CEO	Tel: +354 515 1300
Sveinn Sölvason, CFO	Tel: +354 515 1300
Eva Sóley Guðbjörnsdóttir, VP of IR	Tel: +354 664 1155

Össur press releases by e-mail

If you wish to receive Össur press releases by e-mail please register at the web-site: www.ossur.com/investormailings.

About Össur

Össur (NASDAQ: OSSR) is a global leader in non-invasive orthopaedics that helps people live a life without limitations. Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of braces, supports, prosthetic limbs and compression therapy. A recognized "Technology Pioneer", Össur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur's educational programs and business solutions. Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com

Forward-Looking Statements

This press release includes "forward-looking statements" which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Össur hf. undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

Össur hf.

**Condensed Interim Consolidated
Financial Statements**

March 31st 2015

Table of Contents

Statement by the Board of Directors and President and CEO	7
Consolidated Income Statement	8
Consolidated Statement of Comprehensive Income	9
Consolidated Balance Sheet	10
Consolidated Statements of Cash Flow	12
Consolidated Statement of Changes in Equity	13
Notes to the Condensed Consolidated Financial Statement	14

Statement by the Board of Directors, President and CEO

The Condensed Interim Consolidated Financial Statements of Össur hf. for the period from 1 January to 31 March 2015 consist of the Financial Statements of Össur hf. and its subsidiaries. The Condensed Interim Consolidated Financial Statements are prepared in accordance with International Financial Reporting Standards for Interim Financial Reporting, IAS 34, as adopted by the EU. The Condensed Interim Consolidated Financial Statements are neither audited nor reviewed by the Company's auditors.

The total sales of the Össur Consolidation amounted to USD 113.8 million and the net profit amounted to USD 9.0 million. Össur's Consolidated total assets amounted to USD 646.1 million at the end of period, liabilities were USD 221.4 million, and equity was USD 424.7 million.

It is our opinion that these Condensed Interim Consolidated Financial Statements present all the information necessary to give a true and fair view of the Company's financial position at 31 March 2015 and operating performance of the period ended 31 March 2015.

The Board of Directors and the President and CEO of Össur hf. have today discussed the Condensed Interim Consolidated Financial Statements for the period from 1 January to 31 March 2015 and confirm them by means of their signatures.

Reykjavík, 29 April 2015

Board of Directors

Niels Jacobsen
Chairman of the Board

Arne Boye Nielsen

Kristján T. Ragnarsson

Guðbjörg Edda Eggertsdóttir

Svafa Grönfeldt

President and CEO

Jón Sigurðsson

Consolidated Income Statement 1.1. - 31.3.2015 and 1.1. - 31.3.2014

All amounts in USD '000	Notes	2015 YTD	2014 YTD
Net sales	3	113,785	120,902
Cost of goods sold		(42,431)	(45,305)
Gross profit		71,354	75,597
Other income		29	8
Sales and marketing expenses		(38,671)	(41,855)
Research and development expenses		(4,334)	(5,239)
General and administrative expenses		(12,184)	(12,673)
Earnings before interest and tax (EBIT)		16,194	15,838
Financial income		58	31
Financial expenses		(846)	(881)
Net exchange rate difference		(3,008)	330
Net financial income / (expenses)	5	(3,796)	(520)
Share in net profit / (loss) of associated companies		(226)	6
Earnings before tax (EBT)		12,172	15,324
Income tax		(3,220)	(4,026)
Net profit		8,952	11,298
Attributable to:			
Owners of the Company		8,929	11,215
Non-controlling interests		23	83
		8,952	11,298
Earnings per share	6		
Basic earnings per share (US cent)		2.0	2.5
Diluted earnings per share (US cent)		2.0	2.5

Consolidated Statement of Comprehensive Income

1.1. - 31.3.2015 and 1.1. - 31.3.2014

All amounts in USD '000	Notes	2015	2014
		YTD	YTD
Net profit		8,952	11,298
Items that may be reclassified subsequently to profit or loss:			
Change in cash flow hedges		113	190
Translation difference of shares in foreign operations		(17,948)	(630)
Income tax relating to components of other comprehensive income		(1,163)	(36)
		(18,998)	(476)
Total comprehensive income		(10,046)	10,822
Attributable to:			
Owners of the Company		(10,068)	10,739
Non-controlling interests		23	83
		(10,046)	10,822

Consolidated Balance Sheet 31 March 2015 and 31 December 2014

Assets

All amounts in USD '000	Notes	31.3.2015	31.12.2014
Property, plant and equipment	8	39,419	39,895
Goodwill	9	369,552	388,100
Other intangible assets	10	37,351	41,039
Other financial assets		9,269	10,007
Deferred tax assets		19,873	21,038
Non-current assets		475,464	500,079
Inventories		65,360	64,224
Accounts receivables		69,793	69,474
Other assets		14,269	15,522
Bank balances and cash	11	21,199	28,484
Current assets		170,621	177,704
Total assets		646,085	677,783

Consolidated Balance Sheet 31 March 2015 and 31 December 2014

Equity and liabilities

All amounts in USD '000	Notes	31.3.2015	31.12.2014
Issued capital		169,198	169,198
Reserves		(40,239)	(21,421)
Retained earnings		294,448	293,055
Equity attributable to owners of the Company		423,407	440,832
Non-controlling interest in equity		1,316	1,292
Total equity		424,723	442,124
Borrowings		118,070	121,718
Defined employee benefits		258	283
Deferred tax liabilities		20,227	21,335
Provisions		6,498	6,629
Other financial liabilities		329	471
Non-current liabilities		145,382	150,436
Borrowings		104	101
Accounts payable		18,161	17,504
Taxes payable		11,808	12,651
Provisions		3,488	3,770
Accrued salaries and related expenses		25,312	28,101
Other liabilities		17,107	23,096
Current liabilities		75,980	85,223
Total equity and liabilities		646,085	677,783

Consolidated Statement of Cash Flow 1.1. - 31.3.2015 and 1.1. - 31.3.2014

All amounts in USD '000	Notes	2015 YTD	2014 YTD
Profit from operations		16,194	15,838
Depreciation and amortization	8, 10	4,611	4,422
(Gain) / loss on disposal of assets		22	6
Change in provisions		(126)	73
Changes in operating assets and liabilities		(13,468)	(8,280)
Cash generated by operations		7,233	12,059
Interest received		104	6
Interest paid		(726)	(920)
Income tax (paid)/received		(3,799)	(2,457)
Net cash provided by operating activities		2,812	8,688
Purchase of fixed and intangible assets	8, 10	(4,848)	(2,685)
Proceeds from sale of fixed assets		2	1
Acquisition of subsidiaries			(5,491)
Changes in financial assets		210	52
Cash flows from investing activities		(4,636)	(8,123)
Proceeds from long-term borrowings		4,417	2,051
Repayments of long-term borrowings		(908)	(5,050)
Payment of dividends		(7,536)	(8,399)
Dividends from subsidiaries paid to non-controlling interests		0	(20)
Cash flows from financing activities		(4,027)	(11,418)
Net change in cash		(5,851)	(10,853)
Effects of exchange rate changes on:			
Balance of cash held in foreign currencies		(3,309)	(42)
Other items held in foreign currencies		1,875	(3)
Cash at beginning of period		28,484	41,769
Cash at end of period		21,199	30,871

Additional information regarding cash flow

7

Consolidated Statement of Changes in Equity 1.1. - 31.3.2015 and 1.1. - 31.3.2014

All amounts in USD '000	Share capital	Share premium	Statutory reserve	Share option reserve	Fair value reserve	Translation reserve	Accumulated profits	Attributable to owners of the parent	Non-controlling interests	Total equity
Balance at 1 January 2014	5,048	193,317	1,267	1,321	(735)	2,230	244,202	446,650	1,387	448,037
Net profit							11,215	11,215	83	11,298
Change in cash flow hedges net of tax					151			151		151
Translation difference of shares in foreign operations						(627)		(627)		(627)
Total comprehensive income for the period	0	0	0	0	151	(627)	11,215	10,739	83	10,822
Payment of dividends							(8,399)	(8,399)	(20)	(8,419)
Share option charge for the period				182				182		182
Share option vested during the period				(378)				(378)		(378)
Balance at 31 March 2014	5,048	193,317	1,267	1,125	(584)	1,603	247,018	448,794	1,450	450,244
Balance at 1 January 2015	4,968	164,230	1,267	1,571	(857)	(23,402)	293,055	440,832	1,292	442,124
Net profit							8,929	8,929	23	8,952
Change in cash flow hedges net of tax					86			86		86
Translation difference of shares in foreign operations						(19,084)		(19,084)		(19,084)
Total comprehensive income for the period	0	0	0	0	86	(19,084)	8,929	(10,069)	23	(10,046)
Payment of dividends							(7,536)	(7,536)		(7,536)
Share option charge for the period				180				180		180
Balance at 31 March 2015	4,968	164,230	1,267	1,751	(771)	(42,486)	294,448	423,407	1,316	424,723

In accordance with resolutions from the Annual General Meeting on 12 March 2015, the share capital was decreased in April by ISK 7,456,755 by cancelling the Company's own shares of ISK 1 nominal value each. The Company currently holds 4,650,000 own shares.

Notes to the Consolidated Financial Statements

1. Summary of Significant Accounting Policies

1.1 Statement of compliance

The Condensed Interim Consolidated Financial Statements are prepared in accordance with International Financial Reporting Standards for Interim Financial Reporting, IAS 34 as adopted by the EU. The Condensed Interim Consolidated Financial Statements are presented in accordance with the new and revised standards (IFRS / IAS) and new interpretations (IFRIC), applicable in the period. The implementation of new and revised standards did not have any impact on the Company's Financial Statements. The Company has not early applied new and revised IFRSs that have been issued but are not yet effective. The Financial Statements are presented in USD, which is the Company's functional currency. They do not include all of the information required for full annual Financial Statements and should be read in conjunction with the Company's Annual Financial Statements for the period ended 31 December 2014. The Company's Annual Financial Statements can be found on Company's website www.ossur.com.

1.2 Basis of preparation

The Consolidated Financial Statements have been prepared under the historical cost basis except for certain financial instruments that are measured at fair values. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The accounting policies adopted are consistent with those followed in the preparation of the Company's Annual Financial Statements for the period ended 31 December 2014.

2. Quarterly statements

	Q1 2015	Q4 2014	Q3 2014	Q2 2014	Q1 2014
Net sales	113,785	129,300	126,510	132,645	120,902
Cost of goods sold	(42,431)	(47,823)	(45,517)	(47,586)	(45,305)
Gross profit	71,354	81,477	80,993	85,059	75,597
Gross profit margin	63%	63%	64%	64%	63%
Other income	29	68	37	75	8
Sales and marketing expenses	(38,671)	(43,248)	(39,747)	(43,446)	(41,855)
Research and development expenses	(4,334)	(4,583)	(4,682)	(4,924)	(5,239)
General and administrative expenses	(12,184)	(12,600)	(12,183)	(12,195)	(12,673)
EBIT	16,194	21,114	24,418	24,569	15,838
Net financial income /(expenses)	(788)	(997)	(582)	(1,332)	(850)
Net exchange rate difference	(3,008)	(1,965)	(2,569)	(147)	330
Share in profit of associated companies	(226)	(5)	(4)	3	6
EBT	12,172	18,147	21,263	23,093	15,324
Income tax	(3,220)	(3,248)	(5,249)	(5,846)	(4,026)
Net profit	8,952	14,899	16,014	17,247	11,298
EBITDA	20,805	26,021	28,970	29,085	20,261
EBITDA ratio	18%	20%	23%	22%	17%

3. Net sales

	YTD 2015	YTD 2014
Specified according to geographical segments:		
EMEA	56,678	65,489
Americas	48,925	48,464
APAC	8,182	6,949
	113,785	120,902
Specified according to product lines:		
Bracing and Supports	65,792	72,052
Prosthetics	47,657	48,614
Other products	336	236
	113,785	120,902

Notes to the Consolidated Financial Statements

4. Sales and expenses split by main currencies

Sales	YTD 2015			YTD 2014		
	LCY	USD	%	LCY	USD	%
USD	47,587	47,587	42%	48,950	48,950	40%
EUR	28,120	31,674	28%	26,845	36,781	30%
ISK	42,682	320	0%	40,311	353	0%
Nordic curr. (SEK, NOK, DKK)		16,514	15%		20,633	17%
Other (GBP, AUD, CAD & Other)		17,689	16%		14,185	12%
		113,785	100%		120,902	100%

COGS and OPEX	YTD 2015			YTD 2014		
	LCY	USD	%	LCY	USD	%
USD	40,932	40,932	42%	42,617	42,617	41%
EUR	17,373	19,569	20%	16,752	22,952	22%
ISK	1,427,175	10,690	11%	1,324,513	11,589	11%
Nordic curr. (SEK, NOK, DKK)		17,758	18%		20,069	19%
Other (GBP, MXN, CAD & Other)		8,642	9%		7,836	7%
		97,591	100%		105,064	100%

LCY amounts are translated at average exchange rates for relevant periods.

5. Financial income / (expenses)

	YTD 2015	YTD 2014
Interests on bank deposits	40	12
Other financial income	18	19
Financial income	58	31
Interests on loans	(673)	(732)
Other financial expenses	(173)	(149)
Financial expenses	(846)	(881)
Net exchange rate differences	(3,008)	330
Net financial income / (expenses)	(3,796)	(520)

6. Earnings per share

	YTD 2015	YTD 2014
Net profit	8,952	11,298
Total weighted average number of ordinary shares (in thousands)	441,643	451,507
Total average number of shares including potential shares (in thousands)	445,653	453,222
Basic earnings per share (US cent)	2.0	2.5
Diluted earnings per share (US cent)	2.0	2.5
Cash earnings per share	3.1	3.5
Diluted cash earnings per share	3.0	3.5

Notes to the Consolidated Financial Statements

7. Additional information regarding cash flow

	YTD 2015	YTD 2014
Net profit	8,952	11,298
Items not affecting cash	5,470	5,544
Working capital provided by operating activities	14,422	16,842
(Increase) / decrease in inventories	(5,008)	(3,309)
(Increase) / decrease in receivables	(3,704)	(3,485)
Increase / (decrease) in payables	(2,898)	(1,360)
Net cash provided by operating activities	2,812	8,688

8. Property, plant and equipment

2015	Buildings & sites	Machinery & equipment	Fixtures & office equip.	Total
Cost				
At 1 January	13,145	61,428	30,858	105,431
Additions	0	2,571	1,147	3,718
Exchange rate differences	(1,539)	(2,705)	(1,247)	(5,491)
Eliminated on disposal	0	(43)	(7)	(50)
Fully depreciated assets	0	(180)	(28)	(208)
At 31 March 2015	11,606	61,071	30,723	103,400
Depreciation				
At 1 January	8,409	39,245	17,883	65,537
Charge for the period	91	1,689	815	2,595
Exchange rate differences	(989)	(2,112)	(841)	(3,942)
Eliminated on disposal	23	(27)	3	(1)
Fully depreciated assets	0	(180)	(28)	(208)
At 31 March 2015	7,534	38,615	17,832	63,981
At 31 March 2015	4,072	22,456	12,891	39,419

Depreciation classified by operational category:	YTD 2015	YTD 2014
Cost of goods sold	1,489	1,348
Sales and marketing expenses	345	384
Research and development expenses	97	91
General and administrative expenses	664	783
	2,595	2,606

9. Goodwill

	31.3.2015	31.12.2014
At 1 January	388,100	396,601
Arising on acquisition of subsidiaries	0	15,941
Exchange rate differences	(18,548)	(24,442)
At 31 March 2015	369,552	388,100

The carrying amount of goodwill was allocated to the following cash-generating units:

	31.3.2015	31.12.2014
Americas	221,932	223,790
EMEA	131,299	146,857
APAC	16,321	17,453
	369,552	388,100

Notes to the Consolidated Financial Statements

10. Other intangible assets

2015	Cust./distrib relationships	Patents	Trademarks	Software and other	Total
Cost					
At 1 January	32,912	3,741	14,641	27,484	78,778
Additions	0	10	0	636	646
Additions - internally generated	0	0	0	484	484
Exchange rate differences	(2,684)	(141)	(1,751)	(328)	(4,904)
At 31 March 2015	30,228	3,610	12,890	28,276	75,004
Amortization					
At 1 January	20,841	1,646	597	14,656	37,740
Charge for the period	925	35	0	1,056	2,016
Exchange rate differences	(1,696)	(104)	(156)	(147)	(2,103)
At 31 March 2015	20,070	1,577	441	15,565	37,653
At 31 March 2015	10,158	2,033	12,449	12,711	37,351

Amortization classified by operational category:	YTD 2015	YTD 2014
Cost of goods sold	263	141
Sales and marketing expenses	1,291	1,275
Research and development expenses	5	40
General and administrative expenses	457	360
	2,016	1,816

11. Bank balances and cash

	31.3.2015	31.12.2014
Bank accounts	18,520	24,897
Bankers draft received	2,609	3,516
Cash and other cash equivalents	70	71
	21,199	28,484

Notes to the Consolidated Financial Statements

12. Share option contracts

	Number of shares	Grant/Issue year	Exercise year	Exercise price (in DKK)	Fair value at grant date (in DKK)
Issued to executive management:					
Jón Sigurðsson President and CEO	1,250,000	2012	2015	8.6	8.8
Members of executive management (4 persons)	1,600,000	2012	2015	8.6 / 8.7	8.8
Members of executive management (2 persons)	700,000	2013	2016	7.8 / 7.9	7.4 / 7.9
Member of executive management	250,000	2015	2018	19.4	19.0
	3,800,000				
Issued to management team:					
Eighteen managers	1,800,000	2012	2015	8.7	8.8
Six managers	600,000	2013	2016	7.7 - 7.9	7.4 - 7.9
Six managers	550,000	2015	2018	19.4	19.0
	2,950,000				
Total issued option contracts	6,750,000				

Movements in share options during the period

	31.3.2015		31.12.2014	
	Number of shares	Weighted average contract rate (in DKK)	Number of shares	Weighted average contract rate (in DKK)
Outstanding at beginning of period	5,950,000	8.4	6,350,000	8.3
Granted during period	800,000	19.4	0	0.0
Exercised during period	0	0.0	(400,000)	6.2
Outstanding at end of period	6,750,000	9.7	5,950,000	8.4

Estimated remaining cost due to the share option contracts is USD 0.5 million. An expense of USD 0.2 million (2014: USD 0.2 million) is recognized in the Income Statement for the period.